Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized... PURPOSESERENA-3 is a presurgical window-of-opportunity (WOO) trial exploring the pharmacodynamic effects of camizestrant in postmenopausal women with newly diagnosed estrogen receptor (ER)–positive, h...

Camizestrant 75 mg OD es bien tolerado y alcanza una reducción máxima del receptor estrogénico a través de antagonismo y degradación a los 5 a 7 d, y supresión de la proliferación a los 12 a 15 d en pac c/CA mama ER+ HER2- #camizestrant #breastcancer

#PinkOctober: #Cambria-2 Trial #GBG115: international phase III clinical trial exploring whether #SERD #Camizestrant can offer better protection against recurrence than standard adjuvant endocrine therapy in pts with early-stage ER+/HER2- breast cancer www.gbg.de/en/trials/ca...

#PinkOctober: we highlight the #Cambria-1 #GBG110 trial – a study that offers new perspectives for pts with early-stage ER+/HER2- #breastcancer
Goal: Compare invasive breast cancer-free survival between pts receiving #Camizestrant and those continuing on standard therapy 👉 www.gbg.de/en/trials/ca...

#Medsky🧪 #Oncosky #pharmsky Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with #aromataseinhibitors combined with CDK4/6 inhibitors for advanced #breastcancer. #Camizestrant ER degrader & ER antagonist shows antitumour activity in ER +ve advanced bc

Early camizestrant therapy keeps advanced breast cancer in check Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains quality of life in patients with ESR1-mutated, hormone receptor-positive advanced...

Early camizestrant therapy keeps advanced breast cancer in check www.news-medical.net/news/2025060... #breastcancer #oncology #camizestrant #SERD #ESR1 #clinicaltrial @nejm.org

Are serial liquid biopsies finally ready for prime time?

If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.

That means #ctDNA won’t just monitor—it could guide treatment.

@ascocancer.bsky.social
#bcsm

Learn more about the CAMBRIA-1 & CAMBRIA-2 phase III trials on #camizestrant versus standard #EndocrineTherapy in ER+/HER2- early #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/40017004/
✍️@erikahamilton9.bsky.social @michaelgnant.bsky.social
@stolaney1.bsky.social @barbarapistill2.bsky.social

AstraZeneca boekt doorbraak met veelbelovende behandeling voor borstkanker AstraZeneca heeft positieve resultaten bekendgemaakt van een klinische studie rond Camizestrant, een experimentele behandeling voor borstkanker. De combinatie van dit middel met een standaardtherapie toont een aanzienlijke verbetering in de…

AstraZeneca boekt doorbraak met veelbelovende behandeling voor borstkanker #AstraZeneca #Camizestrant #borstkanker #kankeronderzoek #gezondheid

AstraZeneca’s Camizestrant toont veelbelovend in gevorderde behandeling van borstkanker Key takeaways AstraZeneca kondigde positieve resultaten aan van een klinische studie waarin hun experimentele behandeling tegen borstkanker, Camizestrant, werd geëvalueerd. De studie toonde aan dat Camizestrant, in combinatie met een standaardtherapie die…

AstraZeneca’s Camizestrant toont veelbelovend in gevorderde behandeling van borstkanker #AstraZeneca #Camizestrant #borstkanker #klinischeStudies #gezondheidszorg

Le camizestrant d’AstraZeneca s’avère prometteur dans le traitement du cancer du sein au stade avancé Principaux renseignements AstraZeneca a annoncé les résultats positifs d’un essai clinique évaluant son traitement expérimental du cancer du sein, le camizestrant. L’essai a démontré que le Camizestrant, associé à un traitement standard visant à inhiber…

Le camizestrant d’AstraZeneca s’avère prometteur dans le traitement du cancer du sein au stade avancé #CancerDuSein #Camizestrant #AstraZeneca #EssaiClinique #Santé

AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study - PMLiVE More than two million cases of the disease were diagnosed globally in 2022

pmlive.com/pharma_news/...

AstraZeneca’s #camizestrant shows promise in phase 3 #breastcancer study #medsky

Camizestrant improves breast cancer survival in key trial Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment Camizestrant improved patient survival without the disease getting worse in a study, a positive outcome in the development of the therapy key to the company’s pipeline. Camizestrant, in combination with a standard of care agent designed to suppress proteins that spur tumour growth, showed […]